LOTUSATE
LOE ApproachingNDAORALTABLET
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTUSATE is an oral tablet small molecule approved in 1954 under NDA by Sanofi. The specific indication and mechanism of action are not documented in available data, limiting clinical characterization. This vintage product represents a legacy asset in Sanofi's portfolio.
LOE Approaching
As LOE approaches, the brand team is likely in maintenance mode with minimal headcount expansion and focus on managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss of exclusivity, LOTUSATE offers limited career advancement opportunity. Roles are primarily defensive, focused on protecting market share and managing the transition to generic competition or product discontinuation.
Brand ManagerField Sales Representative
Worked on LOTUSATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.